Medtech firms could see a lot of red tape disappear under a regulatory review proposal from the US Department of Health and Human Services (HHS), experts told Medtech Insight.
The proposal, issued on 4 November, would require that HHS agencies such as the Food and Drug Administration take a fresh look at almost every regulation every ten years. Regs...